The Mind Controls the Body
The Future of Wellness Comes from Psychedelics
NeonMind Biosciences focuses on innovative ways of utilizing psychedelic compounds to improve people’s bodies and minds. Our goal is to address public health needs such as obesity, weight management and mental health through the use of innovative, evidence-backed validated interventional psychiatry treatments, including psychedelics.
Pioneers of Psychedelics for Wellness
NeonMind is the leading company focused on evaluating psychedelics for obesity. Our extensive international patent portfolio protects the therapeutic uses of synthetic and naturally derived psilocybin and derivatives for weight management, giving us an early-mover advantage in a unique clinical indication. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5-HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
Why Psychedelic Medicine
Psychedelics such as MDMA, LSD, and psilocybin are attracting renewed interest in clinical settings worldwide as a promising treatment for depression, anxiety, addiction, and other illnesses. At NeonMind, we are harnessing the potential of psilocybin’s ability to activate serotonin receptors, curb cravings, and reduce appetite to tackle one of the most significant health epidemics of our time—obesity.
Emerging Psychedelic Medicine
In the 1950s and 1960s, psychedelics such as psilocybin and LSD were seen as highly promising psychiatric modalities in several research studies. However, as recreational use of the drugs gained popularity, the FDA banned the drugs and restricted the supply of psychedelics to researchers.
Three decades later, groundbreaking neuroimaging techniques have spurred a resurgence in clinical psychedelic use and psychedelic medicine.
Psychedelic Treatments Today
Today, legislation and regulations regarding psychedelic research have changed. Health Canada and the U.S. Food and Drug Administration (FDA) have recognized the therapeutic merits of psychedelics and have approved psychedelic drugs for the treatment of neuropsychiatric disorders. Furthermore, there are a number of pharmaceutical companies conducting clinical trials for their psychedelic-based drug candidates. As a result, there is growing evidence to support psychedelic medicines as a transformational treatment for many mental health and behavioural disorders. NeonMind is harnessing this novelty to address obesity and weight management, a leading behavioural disorder with major mental health and physical health consequences.
Diversified Businesses Across the Psychedelics Sector
We operate two divisions: a pharmaceutical division developing psilocybin compounds targeting obesity and weight management, and a medical services division establishing specialty mental health clinics to deliver evidence-backed, innovative, currently approved validated interventional psychiatry treatments.
Integrated Pharmaceutical Development
Obesity is a global crisis. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional drug candidate, NEO-002, which employs low-dose psilocybin to control appetite.
Specialized Clinics and Innovative Treatments
Psychedelics and interventional psychiatry are showing promise in treating mood and anxiety disorders, a leading cause of disability in Canada. These specialized medical treatments need to be delivered appropriately for utmost safety and efficacy. NeonMind-branded specialty mental health clinics will bring innovative, evidence-backed validated interventional psychiatry treatments and cutting-edge care across Canada.
Our Core Business Objective: Advance Drug Development & Launch Specialty Clinics
NeonMind’s core objectives for the next two years are: to execute our integrated drug development plan to advance our novel psychedelic compounds into human clinical trials; and to launch NeonMind-branded, specialty mental health clinics to capitalize on innovative, evidenced-backed validated interventional psychiatry treatments. The Company is led by an experienced team of pharmaceutical executives with expertise in drug development and commercial deployment.
The Future of NeonMind
A Shared Vision of Well-Being
Our leadership team has deep experience in pharmaceuticals, drug development and commercialization. We have attracted pioneers from the psychiatry and neuroscience fields to help us understand what is possible when it comes to psychedelics.